Partow Kebriaei, MD, discusses what factors may influence the decision for transplant in patients with acute lymphoblastic leukemia and how experts determine who is best fit for transplant.
A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma ...
In an interview with Targeted Oncology, Chunhui Han, PhD, discussed the use of Ga 68 PSMA-11 for the imaging of metastatic ...
Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...
A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...
The FDA granted traditional approval to selpercatinib for the treatment of advanced or metastatic RET-mutated medullary ...
In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...
Camrelizumab increased the 3-year event-free survival rate vs standard of care from 77.3% to 86.9%, translating to a 44% ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric ...
Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...
GLP-1 agonists, widely used for obesity and diabetes management, have been associated with a reduced risk of most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback